<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04034290</url>
  </required_header>
  <id_info>
    <org_study_id>03 - GamFluVac-2019</org_study_id>
    <nct_id>NCT04034290</nct_id>
  </id_info>
  <brief_title>A Double-blind Randomized Placebo-controlled Study Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac</brief_title>
  <official_title>A Double-blind Randomized Placebo-controlled Study of Safety and Immunogenicity of Medicinal Product With a Period of Open Safety Assessment in Two Modes of Administration, in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Main military clinical hospital named after academician N. N. Burdenko</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present study is at the first stage: a comparative assessment of the safety of&#xD;
      the two methods of vaccine administration, at the second - an assessment of the safety and&#xD;
      state of post-vaccination immunity at different times after vaccination&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the first stage estimate of safety of vaccine after its single administration to the nasal&#xD;
      cavity by the drip method or by spray - dispenser during the period of observation in 30 days&#xD;
      with the participation of 24 volunteers, divided into 2 groups of 12 people for each method&#xD;
      of administration&#xD;
&#xD;
      After interim analysis of safety data is subject to the consent of the local ethics Committee&#xD;
      of the Research Centre about the possibility of further studies of the drug - will be started&#xD;
      the second phase of the study, which, along with continued security research, provides the&#xD;
      definition of the parameters of immunogenicity of the study drug. The second phase of the&#xD;
      study will included 200 participants, including 100 people will receive the study drug and&#xD;
      100 will be a control group of observation - that is, will get a placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 18, 2019</start_date>
  <completion_date type="Actual">July 31, 2020</completion_date>
  <primary_completion_date type="Actual">June 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>This clinical trial on the second stage is designed as a double blind randomized placebo-controlled study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>through the whole study, an average of 180 days</time_frame>
    <description>Determination of Number of Participants With Adverse Events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody levels a measured by an enzyme-linked immunosorbent assay (ELISA)</measure>
    <time_frame>through the whole study, an average of 90 days</time_frame>
    <description>Determination of antibody levels measured by an ELISA vs. baseline values and vs placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of antigen-specific cell-mediated immune response</measure>
    <time_frame>at days 0 and 7</time_frame>
    <description>determination of specific T-cell- mediated response vs. baseline values ans vs placebo</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">224</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Stage 1 (GamFluVac intranasal drip)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The total number of recombinant pseudo-adenoviral particles (2.5 ± 1.25) × 1011 VP/dose administrated by intranasal drip</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1 (GamFluVac with the help of a spray dispenser)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The total number of recombinant pseudo-adenoviral particles (2.5 ± 1.25) × 1011 VP/dose administrated intranasally with the help of a spray dispenser</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2 Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The total number of recombinant pseudo-adenoviral particles (2.5 ± 1.25) × 1011 VP/dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2 (Controll Group)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GamFluVac</intervention_name>
    <description>The drug is a vaccine that induces high-level immunity against influenza A viruses</description>
    <arm_group_label>Stage 1 (GamFluVac intranasal drip)</arm_group_label>
    <arm_group_label>Stage 1 (GamFluVac with the help of a spray dispenser)</arm_group_label>
    <arm_group_label>Stage 2 Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Stage 2 (Controll Group)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Men and women aged 18 to 55 years old.&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
          -  consent to the use of effective contraceptive methods throughout the study period *&#xD;
&#xD;
             * using one of the following methods: abstinence, condoms (male or female with or&#xD;
             without spermicide), diaphragm or cervical cap with spermicide, intrauterine device&#xD;
&#xD;
          -  body mass index (BMI) from 18.5 to 30.&#xD;
&#xD;
          -  absence of acute infectious diseases or exacerbation of chronic infections at the time&#xD;
             of vaccination and 7 days before vaccination;&#xD;
&#xD;
          -  absence of allergic diseases of a serious degree (anaphylactic shock, Quincke's edema,&#xD;
             polymorphic exudative eczema, serum sickness)&#xD;
&#xD;
          -  absence of strong post-vaccination reactions or post-vaccination complications for&#xD;
             previous use of immunobiological drugs;&#xD;
&#xD;
          -  absence of pathology from the gastrointestinal tract, liver, kidneys, cardiovascular&#xD;
             system, central nervous system, musculoskeletal system, genitourinary and endocrine&#xD;
             systems, which may influence the evaluation of the results of the study, in the&#xD;
             anamnesis and also according to the screening examination data;&#xD;
&#xD;
          -  negative pregnancy test (for fertile women);&#xD;
&#xD;
          -  negative tests for HIV, hepatitis B and C, syphilis;&#xD;
&#xD;
          -  negative urine test for traces of drugs;&#xD;
&#xD;
          -  negative test for alcohol content in the exhaled air;&#xD;
&#xD;
          -  absence of malignant blood diseases;&#xD;
&#xD;
          -  absence of malignant neoplasms;&#xD;
&#xD;
          -  indicators of the total blood test at the screening not higher/lower than 1.1 x&#xD;
             LLN/ULN (upper/lower limit of the normal reference range) *;&#xD;
&#xD;
             * normal reference values of the laboratory performing the studies must be provided&#xD;
             before the volunteer screening begins&#xD;
&#xD;
          -  according to the biochemical blood test at the screening: the level of urea,&#xD;
             creatinine, alanine aminotransferase, aspartate aminotransferase, glucose, creatine&#xD;
             phosphokinase, total protein, bilirubin, glucose, LDH, alkaline phosphatase, LDL / HDL&#xD;
             / VLDL - no higher/lower 1.1 X LLN/ULN (upper/lower limit of the normal reference&#xD;
             range), total cholesterol level from 3,6 mmol/l to 7,8 mmol/l;&#xD;
&#xD;
          -  no changes in myocardium of inflammatory or dystrophic nature according to ECG results&#xD;
             at screening;&#xD;
&#xD;
          -  lack of vaccination against influenza within 6 months before the start of the study&#xD;
             (including during participation in other clinical trials).&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  participation of a volunteer in any other study in the last 90 days;&#xD;
&#xD;
          -  any vaccination in the last 30 days;&#xD;
&#xD;
          -  vaccination against influenza within 6 months before the start of the study (including&#xD;
             during participation in other clinical trials).&#xD;
&#xD;
          -  symptoms of respiratory illness in the last 3 days;&#xD;
&#xD;
          -  recent frequent nasal bleeding (&gt; 5 last year);&#xD;
&#xD;
          -  chronic rhinitis, the presence of defects of the nasal septum, polyps of the nose or&#xD;
             other significant anomalies;&#xD;
&#xD;
          -  surgical operations or a history of nasal trauma for 6 months.&#xD;
&#xD;
          -  treatment with steroids in the last 10 days;&#xD;
&#xD;
          -  administration of immunoglobulins or other blood products for the last 3 months;&#xD;
&#xD;
          -  taking immunosuppressive drugs and / or immunomodulators within 6 months before the&#xD;
             start of the study;&#xD;
&#xD;
          -  regular past or current use of narcotic drugs;&#xD;
&#xD;
          -  pregnancy or breastfeeding;&#xD;
&#xD;
          -  systolic blood pressure less than 100 mmHg or higher than 139 mmHg; diastolic blood&#xD;
             pressure less than 60 mmHg. or above 90 mmHg; the heart rate is less than 60 beats per&#xD;
             minute or more than 90 beats per minute;&#xD;
&#xD;
          -  exacerbation of allergic diseases, the presence of anaphylactic reactions or&#xD;
             angioedema in medical history;&#xD;
&#xD;
          -  hypersensitivity or allergic reactions to the administration of any vaccine in medical&#xD;
             history;&#xD;
&#xD;
          -  allergic reactions to vaccine components;&#xD;
&#xD;
          -  diabetes mellitus or other forms of impaired glucose tolerance;&#xD;
&#xD;
          -  the presence of a concomitant disease that may influence the evaluation of the results&#xD;
             of the study: active forms of tuberculosis, chronic liver and kidney diseases, severe&#xD;
             thyroid dysfunction and other endocrine system diseases (diabetes mellitus), severe&#xD;
             deseases of hematopoietic system, epilepsy and other CNS diseases, myocardial&#xD;
             infarction, myocarditis, endocarditis, pericarditis, coronary heart disease,&#xD;
             autoimmune pathology, serious chronic diseases requiring a hospitalisation;&#xD;
&#xD;
          -  donor blood donation (450 ml and more blood or plasma) less than 2 months before the&#xD;
             start of the study;&#xD;
&#xD;
          -  taking a history of more than 5 units of alcohol (equal 0.25 liters of ethanol) per&#xD;
             week;&#xD;
&#xD;
          -  smoking: more than 10 cigarettes a day;&#xD;
&#xD;
          -  planned hospitalization and / or surgical intervention during the study period, and 4&#xD;
             weeks before the expected date of vaccination.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Irina Gagarina, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal state budgetary institution &quot; Main military clinical hospital named after academician N. N. Burdenko &quot; of the Ministry of Defence of the Russian Federation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Federal state budgetary institution &quot; Main military clinical hospital named after academician N. N. Burdenko &quot; of the Ministry of Defence of the Russian Federation</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 24, 2019</study_first_submitted>
  <study_first_submitted_qc>July 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2019</study_first_posted>
  <last_update_submitted>August 23, 2020</last_update_submitted>
  <last_update_submitted_qc>August 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>influenza</keyword>
  <keyword>vaccine</keyword>
  <keyword>Immunologic Factors</keyword>
  <keyword>Respiratory Tract Infections</keyword>
  <keyword>vector vaccines</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

